Navigation Links
Albireo Announces Positive Clinical Data on A3309 in Patients with Chronic Idiopathic Constipation
Date:11/18/2009

GOTHENBURG, Sweden, November 18 /PRNewswire/ -- Albireo today announced the completion of a phase 1b study showing a favorable tolerability and safety profile of A3309 in patients with chronic idiopathic constipation. In addition, the data revealed appropriate efficacy signals in this patient population. A3309 is a first in class compound developed for the treatment of chronic idiopathic constipation and constipation-predominant Irritable Bowel Syndrome (IBS-C). Based on these results, Albireo expects to recruit 180 patients with chronic idiopathic constipation in a US phase 2b study (http://www.clinicaltrials.gov) under an IND recently placed into effect by the FDA.

Notes for Editors:

About CIC

Constipation is one of the most common gastrointestinal complaints. Chronic idiopathic constipation is a more severe and disabling disease, which is not effectively managed by current treatment options. More than 4 million Americans have chronic constipation resulting in 9 million physician visits annually and in addition lead to more than 92,000 hospitalizations annually. In a survey study of 557 individuals with chronic constipation, 47% of respondents indicated a lack of satisfaction with treatment (82% citing lack of treatment efficacy as the reason for dissatisfaction).

About A3309

A3309 is a therapeutic alternative with a novel mechanism of action developed for the treatment of chronic idiopathic constipation and constipation-predominant Irritable Bowel Syndrome (IBS-C). A3309 modulates the re-uptake of bile acids by inhibiting the ileal bile acid transporter. This will result in an increased concentration of bile acids in the colon which, in turn, increase fluid secretion and colonic motility. These physiological responses should provide benefits to patients with chronic constipation and IBS-C without any effects on other parts of the gastrointestinal tract.

About Albireo

Albireo is an independent Swedish biotechnology company focused on the development of novel therapeutic alternatives to fulfill medical needs in the gastrointestinal area. Albireo was spun-out of AstraZeneca in February 2008 and is financed by a syndicate of growth capital firms, including Nomura Phase4 Ventures, TPG growth, TVM Capital and Scottish Widows Investment Partnership. The company has raised $40m in its Series A financing round (http://www.albireopharma.com).

SOURCE Albireo


'/>"/>
SOURCE Albireo
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... York, NY & Greenwich, CT (PRWEB) , ... March 01, 2017 ... ... many runners, especially in the winter months when people don’t want to stop training ... the knees – and setting the treadmill to a small incline can help protect ...
(Date:3/1/2017)... ... , ... “McFarnia”: a suspenseful tale of a father who vanishes without a ... disappearance. “McFarnia” is the creation of published author Tony Pierzchala, a former Army man, ... a Chaplain with Transport for Christ at a truck stop in the Greensboro area. ...
(Date:3/1/2017)... ... ... of Love”: a tale of young love and war. ““Letter of Love”” is the ... Salvador, wife, mother, and co-founder of a Christian College. , “I turned to ... poor communities, and I study psychology. I lived the civil war. ” --Maria Teresa ...
(Date:3/1/2017)... ... , ... “The Affair is Over Now Go Live Your Life Abundantly”: a ... affair. “The Affair is Over Now Go Live Your Life Abundantly” is the creation ... dedicated her professional life to teaching and writing about marriage and family life in ...
(Date:2/28/2017)... ... , ... Answering strong demand for its medical device software design and development ... in the Soma neighborhood in San Francisco on March 1, 2017. The opening also ... systems architecture subject matter experts. , Orthogonal serves a sizeable clientele in the Bay ...
Breaking Medicine News(10 mins):
(Date:3/1/2017)... 1, 2017 The Thyroid Pharmacist, Dr. ... foremost authorities on the thyroid and thyroid conditions, as ... activism, has designed and launched a revolutionary new 9-part ... deeps into the realities of thyroid disease, dispelling the ... path to recovery.  Dr. Wentz, who graduated ...
(Date:3/1/2017)... MINNEAPOLIS , March 1, 2017 Bio-Techne ... -based DK Diagnostics to release its first diagnostic ... is an innovative parasitological system which contains the ... The PARATEST system will be manufactured at Bio-Techne,s ... site and leverages its state-of-art formulation, manufacturing, ...
(Date:3/1/2017)... , March 1, 2017  Integrated ... in the design and implementation of pre-fabricated ... and patient room headwalls, seeks to lead ... and higher-quality solutions. Fueled by ... products capable of reducing construction timelines and ...
Breaking Medicine Technology: